ID: ALA4458933

Max Phase: Preclinical

Molecular Formula: C16H22N4OS2

Molecular Weight: 350.51

Molecule Type: Unknown

Representations

Canonical SMILES:  CC(=O)Nc1nc(C)c(-c2csc(N(C)C3CCCCC3)n2)s1

Standard InChI:  InChI=1S/C16H22N4OS2/c1-10-14(23-15(17-10)18-11(2)21)13-9-22-16(19-13)20(3)12-7-5-4-6-8-12/h9,12H,4-8H2,1-3H3,(H,17,18,21)

Standard InChI Key:  QAVVZXNUWOEKCV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 350.51

Molecular Weight (Monoisotopic): 350.1235

AlogP: 4.30

#Rotatable Bonds: 4

Polar Surface Area: 58.12

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.98

CX Basic pKa: 1.78

CX LogP: 3.97

CX LogD: 3.87

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.89

Np Likeness Score: -2.00

References

1. Tassini S, Langron E, Delang L, Mirabelli C, Lanko K, Crespan E, Kissova M, Tagliavini G, Fontò G, Bertoni S, Palese S, Giorgio C, Ravanetti F, Ragionieri L, Zamperini C, Mancini A, Dreassi E, Maga G, Vergani P, Neyts J, Radi M..  (2019)  Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach †.,  62  (23): [PMID:31729878] [10.1021/acs.jmedchem.9b01416]

Source

Source(1):

• Scientific Literature